IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10221163 B1

PDFFull Text
Date of Patent:
Mar. 05, 2019

Filed:

Jun. 24, 2016

Metallo-beta-lactamase inhibitors

Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Frank Bennett, Cranford, NJ (US);

Jinlong Jiang, Scotch Plains, NJ (US);

Alexander Pasternak, Princeton, NJ (US);

Shuzhi Dong, Plainsboro, NJ (US);

Xin Gu, Scotch Plains, NJ (US);

Jack D. Scott, Scotch Plains, NJ (US);

Haiqun Tang, Belle Mead, NJ (US);

Zhiqiang Zhao, Scotch Plains, NJ (US);

Yuhua Huang, Westfield, NJ (US);

Dexi Yang, Livingston, NJ (US);

Katherine Young, Metuchen, NJ (US);

Li Xiao, Cranbury, NJ (US);

Zhibo Zhang, Beijing, CN;

Jianmin Fu, Beijing, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Eric A. Meade

John C. Todaro

Primary Examiner:

Kahsay Habte

Int. Cl.
CPC ...
C07D 403/14 (2006.01); C07D 403/10 (2006.01); C07D 403/12 (2006.01); C07D 413/14 (2006.01); C07D 401/10 (2006.01); C07D 407/14 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); A61P 31/04 (2006.01); A61K 31/416 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/428 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/4709 (2006.01); A61K 31/4725 (2006.01); A61K 31/498 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 401/14 (2006.01); C07D 487/04 (2006.01); A61K 31/198 (2006.01); A61K 31/407 (2006.01); A61K 31/41 (2006.01); A61K 31/4192 (2006.01); A61K 31/4196 (2006.01); A61K 31/421 (2006.01); A61K 31/4245 (2006.01); A61K 31/431 (2006.01); A61K 31/439 (2006.01); A61K 31/496 (2006.01); A61K 31/541 (2006.01); A61K 31/546 (2006.01); C07D 405/14 (2006.01); C07D 453/02 (2006.01); C07D 487/10 (2006.01); C07D 493/04 (2006.01); C07D 493/08 (2006.01); C07D 495/08 (2006.01);
U.S. Cl.
CPC ...
C07D 403/10 (2013.01); A61K 31/198 (2013.01); A61K 31/407 (2013.01); A61K 31/41 (2013.01); A61K 31/416 (2013.01); A61K 31/4184 (2013.01); A61K 31/4192 (2013.01); A61K 31/4196 (2013.01); A61K 31/421 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/4245 (2013.01); A61K 31/431 (2013.01); A61K 31/437 (2013.01); A61K 31/439 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/4709 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/498 (2013.01); A61K 31/506 (2013.01); A61K 31/5025 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/546 (2013.01); A61K 45/06 (2013.01); A61P 31/04 (2018.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01); C07D 417/10 (2013.01); C07D 417/14 (2013.01); C07D 453/02 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 487/10 (2013.01); C07D 493/04 (2013.01); C07D 493/08 (2013.01); C07D 495/08 (2013.01);
Abstract

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Find Patent Forward Citations

Loading…